2015 Fall Seminar Recap

12
Cardiopulmonary Exercise Testing (CPET) Increasing Functional Capacity with Physiology-Guided Therapy

Transcript of 2015 Fall Seminar Recap

Page 1: 2015 Fall Seminar Recap

Cardiopulmonary Exercise Testing (CPET)

Increasing Functional Capacity with

Physiology-Guided Therapy

Page 2: 2015 Fall Seminar Recap

CPET Equipment

Page 3: 2015 Fall Seminar Recap

*Balady et al. Clinician's Guide to Cardiopulmonary Exercise Testing in Adults. A Scientific Statement From the American Heart Association. Circulation. 2010;122:191-225.

Page 4: 2015 Fall Seminar Recap

CPET fills Unmet Diagnostic Need

Detects invisible disorders

Microvascular Ischemia

Diastolic Heart Failure

Pulmonary Circulation Abnormalities

Page 5: 2015 Fall Seminar Recap

Causes of Exercise Intolerance

303 Greensboro patients tested between June 2013 and Sept 2014

Page 6: 2015 Fall Seminar Recap

Ischemic Heart Disease Progression

AtherosclerosisMicrovascular Ischemia

(endothelial dysfunction // ↓ coronary flow reserve)

Macrovascular Obstructive CAD(stress echo + nuclear stress test + coronary angiogram

+ coronary calcium score + carotid intimal thickness)

Page 7: 2015 Fall Seminar Recap

Under-served Populations

Clinical Significance of Detecting Microvascular Ischemia

✓ Cardiac Prevention➢ Optimal Exercise Rx + Medical Therapy

✓ Chronic Angina Patients➢ Optimal Exercise Rx + Medical Therapy

✓ Women’s Heart Disease ➢ Optimal Exercise Rx + Medical Therapy

Page 8: 2015 Fall Seminar Recap

Cardiorespiratory FitnessExercise Capacity

Functional Capacity

(1 MET = 3.5 ml 02/kg/min)

Normal =/> 85%

Mild: 70-84%

Moderate: 60-69%

Moderate to severe: 50-59%

Severe: < 49%

Peak VO2 = Prognosis !!

Page 9: 2015 Fall Seminar Recap

Stroke volume (SV) → O2-pulse

Heart Rate (HR)

Peak VO2 =/> 100%• Good CV function (healthy)• Low resting sympathetic tone

Peak VO2 < 50%• Poor CV function (sick)• High resting sympathetic tone

• Atherosclerosis (CAD)• Cardiomyopathy (systolic & diastolic)• Valve Disease

Stroke Volume (SV)

Establish Baseline• Peak VO2 = 70%• Peak SV = 15

ml/beat• Peak HR = 150

Disease Progression (under treatment – intensify therapy)

Disease Regression (response to treatment -

adequate therapy)

over years

Cardiac Disease Spectrum & Tracking

Page 10: 2015 Fall Seminar Recap

Baseline CPET

• Peak VO2 > 90%

• No LV Dysfunction

Low Risk

• Peak VO2 = 60-150%

• LV Dysfunction

Increased Risk

• Peak VO2 < 60%• LV Dysfunction

High Risk

• Continue current strategy

• Optimize diet/exercise

Treatment

• Intensify medical therapy

• Moderate Intensity Exercise Rx

• Consider coronary angiogram

Treatment

• Coronary angiogram

• Intensify medical therapy

• Moderate Intensity Exercise Rx

Treatment

CV Risk Stratification at Any Stage of Atherosclerosis

Page 11: 2015 Fall Seminar Recap

Long Term Management Goals

Individualized VALIDATIONACC Goals for treatment of stable ischemic heart

disease

✓ Improve symptoms

✓ Increase Functional Capacity ❑ Peak VO2

❑ Peak SV (O2-pulse)

Copyright © 2004-2011; Metabolic Testing Services, Cor\p. USA.

Page 12: 2015 Fall Seminar Recap

1117 Perimeter Center West | Suite W-211 | Atlanta, Georgia 30338 | 678-636-3060

Sundeep Chaudhry, MDChief Medical Officer

Business: (678) 636-3062Mobile: (404) 966-1670Fax: (678) 636-3086E-mail: [email protected]

Website: www.mettest.net